UK recommendations for SDHA germline genetic testing and surveillance in clinical practice.

Loading...
Thumbnail Image

Embargo End Date

Authors

Hanson, H
Durkie, M
Lalloo, F
Izatt, L
McVeigh, TP
Cook, JA
Brewer, C
Drummond, J
Butler, S
Cranston, T
Casey, R
Tan, T
Morganstein, D
Eccles, DM
Tischkowitz, M
Turnbull, C
Woodward, ER
Maher, ER
UK Cancer Genetics Centres,

Document Type

Journal Article

Date

2022-03-08

Date Accepted

2022-02-13

Abstract

SDHA pathogenic germline variants (PGVs) are identified in up to 10% of patients with paraganglioma and phaeochromocytoma and up to 30% with wild-type gastrointestinal stromal tumours. Most SDHA PGV carriers present with an apparently sporadic tumour, but often the pathogenic variant has been inherited from parent who has the variant, but has not developed any clinical features. Studies of SDHA PGV carriers suggest that lifetime penetrance for SDHA-associated tumours is low, particularly when identified outside the context of a family history. Current recommended surveillance for SDHA PGV carriers follows an intensive protocol. With increasing implementation of tumour and germline large panel and whole-genome sequencing, it is likely more SDHA PGV carriers will be identified in patients with tumours not strongly associated with SDHA, or outside the context of a strong family history. This creates a complex situation about what to recommend in clinical practice considering low penetrance for tumour development, surveillance burden and patient anxiety. An expert SDHA working group was formed to discuss and consider this situation. This paper outlines the recommendations from this working group for testing and management of SDHA PGV carriers in clinical practice.

Citation

Journal of medical genetics, 2022, pp. jmedgenet-2021-108355 - ?

Source Title

Publisher

BMJ PUBLISHING GROUP

ISSN

0022-2593

eISSN

1468-6244
1468-6244

Research Team

Cancer Genetics Education & Quality Improvement

Notes